Literature DB >> 33867934

Gene4MND: An Integrative Genetic Database and Analytic Platform for Motor Neuron Disease.

Guihu Zhao1,2,3, Zhen Liu1, Mengli Wang4, Yanchun Yuan1, Jie Ni1, Wanzhen Li1, Ling Huang4, Yiting Hu1, Pan Liu1, Xiaorong Hou1, Jifeng Guo1,3,5,6, Hong Jiang1,3,5,6, Lu Shen1,3,5,6, Beisha Tang1,3,5,6, Jinchen Li1,2,3,5, Junling Wang1,3,5,6.   

Abstract

Entities:  

Keywords:  amyotrophic lateral sclerosis; gene; gene ontology analysis; immunomodulation; motor neuron disease; one-stop online database

Year:  2021        PMID: 33867934      PMCID: PMC8047132          DOI: 10.3389/fnmol.2021.644202

Source DB:  PubMed          Journal:  Front Mol Neurosci        ISSN: 1662-5099            Impact factor:   5.639


× No keyword cloud information.

Introduction

Motor neuron diseases (MND) refer to a wide and heterogeneous expanding group of neurodegenerative disorders involving the upper and lower motor neurons, which are characterized by rapidly progressive weakness leading to paralysis and eventually death from respiratory failure. Clinically, it is mainly represented by amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), and progressive bulbar palsy (PBP). As the most common type of MND, the number of patients with ALS is rapidly increasing in part because of population aging. It was estimated that 330,918 patients had been diagnosed with ALS worldwide in 2016 (Marin et al., 2017), but significant geographical differences exist. To date, the pathologic mechanisms of MND are still unclear, and effective treatments are not available yet. Thus, further genetic and molecular research on the underlying mechanisms is warranted. In recent years, significant progress has been made to dissect the genetic architecture of MND. Promising MND candidate genes and rare variants (Rosen, 1993; Gitcho et al., 2008; Sreedharan et al., 2008; Zou et al., 2017) have been revealed by genetic linkage and association, gene expression studies, and convergent functional genomics. Multiple highly significant risk variants have also been successfully identified in genome-wide association studies (GWAS) (Nicolas et al., 2018; Farhan et al., 2019). In addition, differentially expressed genes (DEGs) (Wang et al., 2006; Lederer et al., 2007; Shtilbans et al., 2011; Gregory et al., 2020) and differentially methylated genes (DMGs) (Martin and Wong, 2013; Belzil et al., 2014; Ebbert et al., 2017; Coppedè et al., 2018) have also been associated with MND pathogenesis. Despite these great advances in the genetics and genomics of MND, it is difficult to retrieve pertinent information and to annotate it in an efficient manner. Therefore, it is necessary to conduct thorough collection, systematic integration and detailed annotation of existing genes and mutations underlying MND. In this study, we developed a one-stop database of MND-related genes and variants, Gene4MND, to facilitate analysis of genes and variants related to MND. By systematically searching and manually reviewing the literature in PubMed, we included most of the genes and variants related to MND. Combined with popular genomic data sources, various functional annotation data were integrated into the database. Furthermore, we adopted a scoring system based on the genetic evidence to prioritize genes and performed functional analysis of the prioritized genes.

Methods

Data Collection

To obtain a complete list of genes and variants relevant to MND, systematic searches were performed in the PubMed database prior to August 30, 2020, and then, MND-related publications were reviewed manually. Studies were included if they met all of the following criteria: (1) studies with genetic information about rare variants and relatively common variants, copy number variants (CNVs), DEGs and DMGs in MND patients; (2) the diagnosis criteria were described in detail; and (3) the sequencing method and loci of variants were provided. In addition, information about DEGs and DMGs were also collected from an MND animal model. Reviews, expert opinions, and editorials were excluded. Consequently, a total of 478 studies met the inclusion criteria for further information extraction. Genetic information, basic information and clinical data were extracted through in-depth reading of the full text of each publication. Of note, GGGGCC hexanucleotide repeat expansions in the non-coding region of C9orf72 and CAG trinucleotide repeat expansions in the ATXN2 gene, which have been extensively researched (Vance et al., 2006; DeJesus-Hernandez et al., 2011; Renton et al., 2011; Majounie et al., 2012; Jiao et al., 2014), were considered common genetic causes for ALS. Thus, the nucleotide repeat variations of those two genes were cataloged independently. A summary of major data types is shown in Supplementary Table 1.

Functional Annotation

Sixty-three genomic data sources were integrated to annotate each variant and gene (Supplementary Table 2). At the variant level, ANNOVAR (Wang et al., 2010) was used for comprehensive annotation. It produced not only functional effects of variants (frameshift, non-frameshift, synonymous, non-synonymous, stopgain, stoploss, splicing, and non-coding) but also disease- and phenotype-related information for functional implications. In addition, we annotated the functional consequences of variants through 23 in silico predictive algorithms and provided allele frequencies in different populations of public databases. At the gene level, a comprehensive annotation for each gene was provided, including basic gene information, gene function (molecular function (MF), gene ontology (GO), protein-protein interaction (PPI), and pathway), disease- and phenotype-related information, gene expression patterns in the human brain, variants in different populations, and drug-gene interactions, as in our previous databases, VarCards and Gene4Denovo (Li et al., 2018; Zhao et al., 2020).

Gene Prioritization

To identify high-confidence genes by their relevance to MND, gene prioritization (except for C9orf72 and ATXN2) was conducted by combining the different types of genetic evidence as follows: a score of five was assigned to CNVs and rare loss-of-function (LoF) variants including stopgain, stoploss, splicing sites, single-nucleotide variants (SNVs), and frameshift indels; scores of 3, 2, and 1 were assigned to rare deleterious missense variants, rare non-synonymous SNVs, and non-synonymous SNVs, respectively; a score of 1–3 was assigned to single-nucleotide polymorphisms (SNPs), DEGs, and DMGs based on their p-values (Supplementary Table 3). Rarity was defined as a minor allele frequency <0.0001 based on gnomAD.

Functional Analysis Based on the Prioritized Genes

Further data mining based on the prioritized genes was performed to schematize the functional relevance of MND-related genes, and genes with a total score of at least 4 were considered prioritized genes. GO analysis of the biological process (BP), cellular component (CC), and MF levels and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the cluster Profiler package. An adjusted p-value < 0.01 was considered statistically significant, and the visualization of results was performed with the GO plot package. A PPI network was constructed using the STRING database, and the minimum required interaction score was 0.4. The core cluster was extracted using the MCODE algorithm in Cytoscape software with a node score cut-off of 0.2 and K-core of 4. GO analysis at the BP, CC, and MF levels and KEGG analysis were further performed based on the genes in the core clusters.

Results

Data and Database Interface

Consequently, except for the polynucleotide expansion of C9orf72 and ATXN2, 916 rare variants, 2,791 common variants, 88 CNVs, 4,004 DEGs, 369 DMGs, and the corresponding detailed genetic and clinical information were integrated into the Gene4MND database (Figure 1, Supplementary Table 1).
Figure 1

Overview of the Gene4MND database. Multiple types of data from various sources were collected and curated. Systematic data and functional annotation from more 60 genomic data sources were integrated into Gene4MND, which contains three core modules providing comprehensive description information and customized analysis.

Overview of the Gene4MND database. Multiple types of data from various sources were collected and curated. Systematic data and functional annotation from more 60 genomic data sources were integrated into Gene4MND, which contains three core modules providing comprehensive description information and customized analysis. A user-friendly web interface, Gene4MND (www.genemed.tech/gene4mnd/), was developed, supported by versatile browsing and searching functionalities, as in our previous databases and web servers (Li et al., 2018; Zhao et al., 2020). All of the data were stored in a MySQL database. Users can access the genetic data or extended analysis results freely through this web interface. The web interface of Gene4MND contains three core modules: the Search, Analysis, and Browse modules (Figure 1). (1) Search module. This module provides two options, Quick Search and Advanced Search, to query variants and genes. Quick Search supports several common search terms, such as gene symbol, genomic region, and variant. In addition to those terms, Advanced Search supports more terms, such as cytoband, variant, transcript, and genomic coordinate, and it supports simultaneously searching several terms. For each query, Gene4MND will generate a summary report that summarizes the evidence score of the gene from the variant types of the collected genetic data, including the rare variant score, associated SNP score, CNV score, DEG score, DMG score, and combined score. The detailed information of the five types of variants is provided in the subsequent five tables. Of note, in the rare variants section, the link Expand row will provide the in silico missense prediction, allele frequency in the population, disease information, and information from the original study of rare variants. (2) Analysis module. Users can perform customized analyses with this module. After inputting genetic data (VCF4 format) and choosing the genotype information of samples, the genetic variants will be analyzed by Gene4MND using default parameters. Of note, users can also specify their cut-off values for quality control, annotation data sources, and parameters for identifying rare damaging variants. To perform comprehensive annotations, the databases for basic information annotation, pathogenicity prediction of missense variants, allele frequency in the variant population, and clinical-related data need to be specified. Gene4MND will send a link to the user by e-mail to download the results when the analysis is complete. (3) Browse module. A total of 3,817 Homo sapiens genes were collated and integrated into Gene4MND. By sourcing from more than 60 genomic data sources, a one-stop interface of a given gene is provided, including basic information, such as the primary information of genes, gene function, phenotype and disease data; gene expression, which provides the spatiotemporal expression profiles and expression in different tissues of specific genes; variants in different populations; and drug-gene interactions. (4) Upload and download module. In addition, this database also provides the ability to upload and download modules, which encourages all laboratories and researchers to upload their variant files and download the datasets that they need. A total of 200 genes with an evidence score >4 were included as prioritized genes, and the top 10 prioritized genes are as follows: SOD1, FUS, TARDBP, TBK1, OPTN, VCP, SETX, FIG4, SQSTM1, and VAPB. Considering that nucleotide repeat expansions in the C9orf72 and ATXN2 genes are commonly considered genetic causes of MND, the C9orf72 and ATXN2 genes were also included in the functional analysis. GO analysis indicated that prioritized genes were significantly enriched in 51 GO terms, including 41 GO terms (80.3%) related to BP and 10 GO terms (19.7%) related to CC, while no GO terms were related to MF. Among the GO terms related to BP, most prioritized genes were included in pathways were related to the immune response (Figures 2A,B), such as neutrophil activation and degranulation, T cell activation, regulation of cytokine production, phagocytosis, and antigen processing and presentation. Among the GO terms related to CC, the majority of prioritized genes were involved in cell granule formation, secretion, and phagocytosis (Figures 2C,D). KEGG analysis revealed that prioritized genes were enriched in the ALS pathway (Figure 2E).
Figure 2

Functional analysis based on the prioritized genes. (A) GO analysis showing the top 10 GO terms related to BP. (B) Heatmap showing the BP clustering of the prioritized genes. (C) GO analysis showing the top 10 GO terms related to CC. (D) Heatmap showing the CC clustering of the prioritized genes. (E) KEGG pathway analysis. (F) Core cluster 1 extracted from the PPI network. (G) Core cluster 2 extracted from the PPI network.

Functional analysis based on the prioritized genes. (A) GO analysis showing the top 10 GO terms related to BP. (B) Heatmap showing the BP clustering of the prioritized genes. (C) GO analysis showing the top 10 GO terms related to CC. (D) Heatmap showing the CC clustering of the prioritized genes. (E) KEGG pathway analysis. (F) Core cluster 1 extracted from the PPI network. (G) Core cluster 2 extracted from the PPI network. Based on the prioritized genes, we extracted two clusters from the constructed PPI network (Figures 2F,G). Genes in cluster 1 were mainly involved in endomembrane system organization, endosomal transport, macro-autophagy, the neuronal cell body, vesicle organization, and the growth cone (Supplementary Table 4). Genes in cluster 2 were mainly involved in the following pathways: positive regulation of cytokine production, neutrophil degranulation, neutrophil activation involved in the immune response, neutrophil activation, and neutrophil-mediated immunity (Supplementary Table 4).

Discussion

With the development of sequencing technologies, a growing number of genetic insights into MND have been revealed (Brenner and Weishaupt, 2019; Mathis et al., 2019; Mejzini et al., 2019). Nevertheless, the pathophysiology of MND remains largely unknown, and the scattered results create a major challenge for interpreting close relationships between genotypes and phenotypes. Therefore, we constructed a comprehensive genetic resource for MND, Gene4MND, to systematically integrate multiple types of data from various studies and to obtain meaningful biological information from genetic findings of MND. Despite the advances of other available databases, such as ALSdb (http://alsod.org/), ALSoD (https://alsod.ac.uk/output/gene.php) (Yoshida et al., 2010), and Project MinE (https://www.als.org/) (Consortium, 2018), Gene4MND, which is designed as a one-stop database of MND variants and genes, has several advantages. First, the web interface of Gene4MND is more user-friendly, and it provides a more intuitive online interface for researchers without sufficient bioinformatics skills to access the first-hand genetic, genomic and clinical information of MND-related variants within a short time. Second, the Gene4MND database not only integrates all of the collected genetic information but also retrieves information from more than 60 genomic data sources. Third, the Gene4MND database evaluates and scores each piece of evidence for specific variants and integrates scattered genetic, genomic, and clinical data sources to prioritize disease-causing or disease risk variations. Of note, Gene4MND provides a platform for custom analysis, and users will be able to flexibly prioritize candidate variations and genes based on genetic data and different criteria according to the needs of the study. Finally, as a database of MND, Gene4MND provides a repository for researchers to further analyse the existing evidence to understand the pathogenesis of ALS. Based on the prioritized genes, GO, KEGG and PPI analysis can be used to help the user understand the complex mechanisms underlying ALS. For example, using GO analysis, we revealed that most MND-related genes are involved in the immune response, which is consistent with previous studies (Mantovani et al., 2009; Hooten et al., 2015; Brown and Al-Chalabi, 2017), suggesting that immunomodulation plays important roles in the pathogenesis of MND. Certainly, there are several issues that should be emphasized. On the one hand, the evidence of clinically significant variations from different studies with differences in criteria and methods of assessing the pathogenicity of genetic variants may lead to bias. On the other hand, users should note the potential limitations with regard to the specificity and sensitivity of the in silico prediction tools. Notably, a continuous rapid increase in data generation and improvement of data quality in MND research in the future is expected, and thus, we will routinely update the database. In conclusion, Gene4MND is a dedicated repository, platform and communication warehouse for MND that aims to accelerate genetic consulting, enhance the understanding of the diseases and facilitate MND research.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author Contributions

JL, JW, JG, HJ, LS, and BT: database design. ZL, GZ, YY, JN, YH, JW, WL, PL, and XH: data collection. GZ, ZL, JW, and JL: database construction and maintenance. ZL, GZ, and MW: data analysis. MW, LH, ZL, GZ, JL, and JW: manuscript writing. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  31 in total

Review 1.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Differential gene expression in patients with amyotrophic lateral sclerosis.

Authors:  Alexander Shtilbans; Soon-Gang Choi; Mary E Fowkes; Greg Khitrov; Mona Shahbazi; Jess Ting; Weijia Zhang; Yezhou Sun; Stuart C Sealfon; Dale J Lange
Journal:  Amyotroph Lateral Scler       Date:  2011-03-04

Review 3.  Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a new target of disease mechanisms.

Authors:  Lee J Martin; Margaret Wong
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  Genetics of amyotrophic lateral sclerosis: A review.

Authors:  Stéphane Mathis; Cyril Goizet; Antoine Soulages; Jean-Michel Vallat; Gwendal Le Masson
Journal:  J Neurol Sci       Date:  2019-02-21       Impact factor: 3.181

Review 5.  Update on amyotrophic lateral sclerosis genetics.

Authors:  David Brenner; Jochen H Weishaupt
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

6.  TDP-43 A315T mutation in familial motor neuron disease.

Authors:  Michael A Gitcho; Robert H Baloh; Sumi Chakraverty; Kevin Mayo; Joanne B Norton; Denise Levitch; Kimmo J Hatanpaa; Charles L White; Eileen H Bigio; Richard Caselli; Matt Baker; Muhammad T Al-Lozi; John C Morris; Alan Pestronk; Rosa Rademakers; Alison M Goate; Nigel J Cairns
Journal:  Ann Neurol       Date:  2008-02-20       Impact factor: 10.422

7.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

8.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

9.  Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Authors:  Aude Nicolas; Kevin P Kenna; Alan E Renton; Nicola Ticozzi; Faraz Faghri; Ruth Chia; Janice A Dominov; Brendan J Kenna; Mike A Nalls; Pamela Keagle; Alberto M Rivera; Wouter van Rheenen; Natalie A Murphy; Joke J F A van Vugt; Joshua T Geiger; Rick A Van der Spek; Hannah A Pliner; Bradley N Smith; Giuseppe Marangi; Simon D Topp; Yevgeniya Abramzon; Athina Soragia Gkazi; John D Eicher; Aoife Kenna; Gabriele Mora; Andrea Calvo; Letizia Mazzini; Nilo Riva; Jessica Mandrioli; Claudia Caponnetto; Stefania Battistini; Paolo Volanti; Vincenzo La Bella; Francesca L Conforti; Giuseppe Borghero; Sonia Messina; Isabella L Simone; Francesca Trojsi; Fabrizio Salvi; Francesco O Logullo; Sandra D'Alfonso; Lucia Corrado; Margherita Capasso; Luigi Ferrucci; Cristiane de Araujo Martins Moreno; Sitharthan Kamalakaran; David B Goldstein; Aaron D Gitler; Tim Harris; Richard M Myers; Hemali Phatnani; Rajeeva Lochan Musunuri; Uday Shankar Evani; Avinash Abhyankar; Michael C Zody; Julia Kaye; Steven Finkbeiner; Stacia K Wyman; Alex LeNail; Leandro Lima; Ernest Fraenkel; Clive N Svendsen; Leslie M Thompson; Jennifer E Van Eyk; James D Berry; Timothy M Miller; Stephen J Kolb; Merit Cudkowicz; Emily Baxi; Michael Benatar; J Paul Taylor; Evadnie Rampersaud; Gang Wu; Joanne Wuu; Giuseppe Lauria; Federico Verde; Isabella Fogh; Cinzia Tiloca; Giacomo P Comi; Gianni Sorarù; Cristina Cereda; Philippe Corcia; Hannu Laaksovirta; Liisa Myllykangas; Lilja Jansson; Miko Valori; John Ealing; Hisham Hamdalla; Sara Rollinson; Stuart Pickering-Brown; Richard W Orrell; Katie C Sidle; Andrea Malaspina; John Hardy; Andrew B Singleton; Janel O Johnson; Sampath Arepalli; Peter C Sapp; Diane McKenna-Yasek; Meraida Polak; Seneshaw Asress; Safa Al-Sarraj; Andrew King; Claire Troakes; Caroline Vance; Jacqueline de Belleroche; Frank Baas; Anneloor L M A Ten Asbroek; José Luis Muñoz-Blanco; Dena G Hernandez; Jinhui Ding; J Raphael Gibbs; Sonja W Scholz; Mary Kay Floeter; Roy H Campbell; Francesco Landi; Robert Bowser; Stefan M Pulst; John M Ravits; Daniel J L MacGowan; Janine Kirby; Erik P Pioro; Roger Pamphlett; James Broach; Glenn Gerhard; Travis L Dunckley; Christopher B Brady; Neil W Kowall; Juan C Troncoso; Isabelle Le Ber; Kevin Mouzat; Serge Lumbroso; Terry D Heiman-Patterson; Freya Kamel; Ludo Van Den Bosch; Robert H Baloh; Tim M Strom; Thomas Meitinger; Aleksey Shatunov; Kristel R Van Eijk; Mamede de Carvalho; Maarten Kooyman; Bas Middelkoop; Matthieu Moisse; Russell L McLaughlin; Michael A Van Es; Markus Weber; Kevin B Boylan; Marka Van Blitterswijk; Rosa Rademakers; Karen E Morrison; A Nazli Basak; Jesús S Mora; Vivian E Drory; Pamela J Shaw; Martin R Turner; Kevin Talbot; Orla Hardiman; Kelly L Williams; Jennifer A Fifita; Garth A Nicholson; Ian P Blair; Guy A Rouleau; Jesús Esteban-Pérez; Alberto García-Redondo; Ammar Al-Chalabi; Ekaterina Rogaeva; Lorne Zinman; Lyle W Ostrow; Nicholas J Maragakis; Jeffrey D Rothstein; Zachary Simmons; Johnathan Cooper-Knock; Alexis Brice; Stephen A Goutman; Eva L Feldman; Summer B Gibson; Franco Taroni; Antonia Ratti; Cinzia Gellera; Philip Van Damme; Wim Robberecht; Pietro Fratta; Mario Sabatelli; Christian Lunetta; Albert C Ludolph; Peter M Andersen; Jochen H Weishaupt; William Camu; John Q Trojanowski; Vivianna M Van Deerlin; Robert H Brown; Leonard H van den Berg; Jan H Veldink; Matthew B Harms; Jonathan D Glass; David J Stone; Pentti Tienari; Vincenzo Silani; Adriano Chiò; Christopher E Shaw; Bryan J Traynor; John E Landers
Journal:  Neuron       Date:  2018-03-21       Impact factor: 18.688

10.  Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3.

Authors:  Caroline Vance; Ammar Al-Chalabi; Deborah Ruddy; Bradley N Smith; Xun Hu; Jemeen Sreedharan; Teepu Siddique; H Jurgen Schelhaas; Benno Kusters; Dirk Troost; Frank Baas; Vianney de Jong; Christopher E Shaw
Journal:  Brain       Date:  2006-02-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.